Bristol Myers Squibb Acquires RayzeBio for $4.1 Billion

The acquisition, Bristol Myers Squibb's second multibillion-dollar deal in a week, expands its cancer treatment portfolio and establishes its presence in the promising field of radiopharmaceutical therapeutics.